Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

• ClinicalTrials.gov Identifier: NCT00861744
• Recruitment Status: Completed
• First Posted: March 13, 2009
• Results First Posted: November 4, 2011
• Last Update Posted: January 3, 2020
• Sponsor: GlaxoSmithKline
• Information provided by (Responsible Party): GlaxoSmithKline

Study Description

Brief Summary:

The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first vaccination. Additionally, antibody persistence will be assessed one and two years after administration of MMR vaccine.

The Protocol Posting has been updated following Protocol amendment 1 and 2, Oct 2009.

Condition or disease	Intervention/treatment	Phase
Rubella; Mumps; Measles; Measles-Mumps-Rubella Vaccine	Biological: GSK Biological's investigational vaccine 209762; Biological: M-M-R® II (Merck and Co); Biological: Varivax®; Biological: Havrix®; Biological: Prevnar®	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1259 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Outcomes Assessor)
• Primary Purpose: Prevention
• Official Title: A Phase II, Randomized, Observer Blind, Controlled, Multicenter Study to Assess Immunogenicity and Antibody Persistence Following Vaccination With GSK's Candidate Combined Measles, Mumps, and Rubella Vaccine (MMR) Versus M-M-R® II as a First Dose, Both Administered Subcutaneously at 12-15 Months of Age, Concomitantly With Hepatitis A Vaccine (HAV), Varicella Vaccine (VV) and Pneumococcal Conjugate Vaccine (PCV) But at Separate Sites.
• Actual Study Start Date: June 3, 2009
• Actual Primary Completion Date: July 21, 2010
• Actual Study Completion Date: June 18, 2012

Arms and Interventions

Arm	Intervention/treatment
Experimental: Priorix 1 Group; Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 1) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.	Biological: GSK Biological's investigational vaccine 209762; Subcutaneous injection, one dose; Biological: Varivax®; Subcutaneous injection, one dose; Biological: Havrix®; Intramuscular injection, one dose; Biological: Prevnar®; Intramuscular injection, one dose
Experimental: Priorix 2 Group; Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 2) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.	Biological: GSK Biological's investigational vaccine 209762; Subcutaneous injection, one dose; Biological: Varivax®; Subcutaneous injection, one dose; Biological: Havrix®; Intramuscular injection, one dose; Biological: Prevnar®; Intramuscular injection, one dose
Experimental: Priorix 3 Group; Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 3) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.	Biological: GSK Biological's investigational vaccine 209762; Subcutaneous injection, one dose; Biological: Varivax®; Subcutaneous injection, one dose; Biological: Havrix®; Intramuscular injection, one dose; Biological: Prevnar®; Intramuscular injection, one dose
Active Comparator: MMR-II Group; Subjects between 12 and 15 months of age at the time of study vaccination who randomly received one dose of one of three different commercially-available lot of M-M-R II (Merck and Co.) vaccine subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.	Biological: M-M-R® II (Merck and Co); Subcutaneous injection, one dose; Biological: Varivax®; Subcutaneous injection, one dose; Biological: Havrix®; Intramuscular injection, one dose; Biological: Prevnar®; Intramuscular injection, one dose

Outcome Measures

Primary Outcome Measures :

1. Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value. [ Time Frame: At Day 42 after administration of a dose of Priorix vaccine. ]
   Anti-measles virus antibody cut-off-value assessed was ≥ 200 milli-International Units per milliliter (mIU/mL). The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-measles virus antibody concentrations <150 mIU/mL prior to vaccination.
2. Number of Subjects With Anti-mumps Virus Antibody Titer Equal to or Above the Cut-off-value. [ Time Frame: At Day 42 after administration of a dose of Priorix vaccine. ]
   Anti-mumps virus antibody cut-off-value assessed was ≥ 51 Estimated Dose 50 (ED50). The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-measles virus antibody concentrations <24 ED50 prior to vaccination.
3. Number of Subjects With Anti-rubella Virus Antibody Concentrations Equal to or Above the Cut-off-value. [ Time Frame: At Day 42 after administration of a dose of Priorix vaccine. ]
   Anti-rubella virus antibody cut-off-value assessed was ≥ 10 International Units per milliliter (IU/mL).

Secondary Outcome Measures :

1. Number of Subjects With Anti-varicella Antibody Concentration Equal to or Above the Cut-off-value. [ Time Frame: At Day 42 after administration of a dose of Varivax vaccine. ]
   Anti-varicella virus antibody cut-off-value assessed was ≥ 75 milli-International Units per milliliter (mIU/mL).
2. Anti-measles Virus Antibody Concentrations [ Time Frame: At Day 42 after administration of a dose of Priorix vaccine. ]
   Antibody concentrations are expressed as Geometric Mean Concentrations (GMCs) in mIU/mL. The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-measles virus antibody concentrations <150 mIU/mL prior to vaccination.
3. Anti-mumps Virus Antibody Concentrations [ Time Frame: At Day 42 after administration of a dose of Priorix vaccine. ]
   Antibody concentrations are expressed as Geometric Mean Titer (GMT). The analysis was performed on seronegative subjects. Seronegative subjects are subjects with antibody titer < 24 ED50 prior to vaccination.
4. Anti-rubella Virus Antibody Concentrations [ Time Frame: At Day 42 after administration of a dose of Priorix vaccine. ]
   Antibody concentrations are expressed as Geometric Mean Concentrations (GMCs) in IU/mL. The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-rubella virus antibody concentrations <4 IU/mL prior to vaccination.
5. Anti-S. Pneumoniae Antibody Concentrations (by Serotype). [ Time Frame: At Day 42 after vaccination ]
   Antibody concentrations are expressed as Geometric Mean Concentrations (GMCs) in µg/mL.
6. Anti-varicella Antibody Concentrations. [ Time Frame: At Day 42 after administration of a dose of Varivax vaccine. ]
   Antibody concentrations are expressed as Geometric Mean Titers (GMT). The analysis was performed on seronegative subjects. Seronegative subjects are subjects with antibody concentration < 25 mIU/mL prior to vaccination.
7. Anti-hepatitis A Virus Antibody Concentrations. [ Time Frame: At Day 42 after administration of a dose of Havrix vaccine. ]
   Antibody concentrations are expressed as Geometric Mean Concentrations (GMCs) in mIU/mL. The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-hepatitis A virus antibody concentrations <15 mIU/mL prior to vaccination.
8. Number of Subjects With Anti-hepatitis A Antibody Concentrations Equal to or Above the Cut-off-value. [ Time Frame: At Day 42 after administration of a dose of Havrix vaccine. ]
   Anti-hepatitis A antibody cut-off-value assessed was ≥15 milli-International Units per milliliter (mIU/mL).
9. Anti-S. Pneumoniae Antibody Concentrations (by Serotype). [ Time Frame: At Day 0 before vaccination ]
   Antibody concentrations are expressed as Geometric Mean Concentrations (GMCs) in µg/mL.
10. Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value [ Time Frame: At 1 year post-vaccination ]
    Anti-measles virus antibody cut-off-value assessed was ≥ 200 milli-International Units per milliliter (mIU/mL).
11. Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value [ Time Frame: At 2 years post-vaccination ]
    Anti-measles virus antibody cut-off-value assessed was ≥ 200 milli-International Units per milliliter (mIU/mL).
12. Anti-measles Virus Antibody Concentrations [ Time Frame: At 2 years post-vaccination ]
    Antibody concentrations are expressed as Geometric Mean Concentrations (GMCs) in mIU/mL. The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-measles virus antibody concentrations <150 mIU/mL prior to vaccination.
13. Anti-measles Virus Antibody Concentrations [ Time Frame: At 1 year post-vaccination ]
    Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs) in mIU/mL. The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-measles virus antibody concentrations <150 mIU/mL prior to vaccination.
14. Number of Subjects Reporting Investigator-confirmed Measles/Rubella-like Rash and Varicella-like Rash. [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
15. Number of Subjects Reporting Febrile Convulsions [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Timing of febrile convulsions: events occured on Day 29 in the Priorix 2 Group and Day 0 in the MMR II Group. All cases of febrile convulsions were case of meningism.
16. Anti-mumps Virus Antibody Titers (Enhanced Plaque Reduction Neutralization (PRN)) [ Time Frame: At 1 year post-vaccination ]
    Antibody titers were expressed as Geometric Mean Titer (GMT). The analysis was performed on seronegative subjects. Seronegative subjects are subjects with antibody titer < 24 ED50 prior to vaccination.
17. Number of Subjects Reporting Other Rash. [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Other rash = not confirmed by the investigator to be either measles/rubella-like or varicella-like in nature
18. Number of Subjects With Anti-mumps Virus Antibody Titers Above the Cut-off Value (Enhanced PRN) [ Time Frame: At 1 year post-vaccination ]
    Anti-mumps virus antibody cut-off-value assessed was ≥ 51 ED50.
19. Number of Subjects With Anti-rubella Virus Antibody Concentrations Equal to or Above the Cut-off-value. [ Time Frame: At 1 year post-vaccination ]
    Anti-rubella virus antibody cut-off-value assessed was ≥ 10 International Units per milliliter (IU/mL). The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-rubella virus antibody concentrations <4 IU/mL prior to vaccination.
20. Number of Subjects With Anti-rubella Virus Antibody Concentrations Equal to or Above the Cut-off-value. [ Time Frame: At 2 years post-vaccination ]
    Anti-rubella virus antibody cut-off-value assessed was ≥ 10 International Units per milliliter (IU/mL).
21. Anti-rubella Virus Antibody Concentrations [ Time Frame: At 1 year post-vaccination ]
    Antibody concentrations are expressed as Geometric Mean Concentrations (GMCs) in IU/mL. The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-rubella virus antibody concentrations <4 IU/mL prior to vaccination.
22. Anti-rubella Virus Antibody Concentrations [ Time Frame: At 2 years post-vaccination ]
    Antibody concentrations are expressed as Geometric Mean Concentrations (GMCs) in IU/mL. The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-rubella virus antibody concentrations <4 IU/mL prior to vaccination.
23. Number of Subjects Reporting Fever. [ Time Frame: During the 15-day (Days 0-14) and 43 days (Days 0-42) post-vaccination period ]
    fever is assessed for temperature ≥38°C/100.4°F and >39.5°C/103.1°F as measured rectally.
24. Number of Subjects With Solicited Local Symptoms. [ Time Frame: During the 4-day (Days 0-3) post-vaccination period ]
    Solicited local symptoms assessed were pain, redness and swelling.
25. Number of Subjects Reporting Medically Attended Visit (MAEs) [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.
26. Number of Subjects With Unsolicited Adverse Events (AEs). [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
27. Number of Subjects Reporting Investigator-confirmed Parotid/Salivary Gland Swelling. [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Swelling with accompanying general symptoms
28. Number of Subjects With Solicited General Symptoms. [ Time Frame: During the 15-day (Days 0-14) post-vaccination period ]
    Assessed solicited general symptoms were drowsiness, irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.
29. Number of Subjects Reporting New Onset Chronic Illnesses (NOCIs). [ Time Frame: From Day 0 to Day 180 after vaccination ]
    NOCIs included autoimmune disorders, asthma, type I diabetes, allergies.
30. Number of Subjects Reporting Serious Adverse Events (SAEs) [ Time Frame: From Day 0 to Day 180 after vaccination ]
    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
31. Number of Subjects Reporting Serious Adverse Events (SAEs). [ Time Frame: From Day 180 to Day 730 after vaccination ]
    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are congenital anomaly/birth defect in the offspring of a study subject.
32. Number of Subjects Reporting Conditions Prompting Emergency Room (ER) Visits. [ Time Frame: From Day 0 to Day 180 after vaccination ]
33. Anti-mumps Virus Antibody Titers (Unenhanced PRN) [ Time Frame: At 1 year post-vaccination ]
    Antibody titers were expressed as Geometric Mean Titer (GMT).
34. Number of Subjects With Anti-mumps Virus Antibody Titers Above the Cut-off Value (Unenhanced PRN) [ Time Frame: At 1 year post-vaccination ]
    Anti-mumps virus antibody cut-off-value assessed was ≥ 4 Estimated Dose 50 (ED50).
35. Anti-mumps Virus Antibody Titers (Unenhanced PRN) [ Time Frame: At 2 years post-vaccination ]
    Antibody concentrations are expressed as Geometric Mean Titer (GMT).
36. Number of Subjects With Anti-mumps Virus Antibody Titers Above the Cut-off Value (Unenhanced PRN) [ Time Frame: At 2 years post-vaccination ]
    Anti-mumps virus antibody cut-off-value assessed was ≥ 4 Estimated Dose 50 (ED50).
37. Anti-mumps Virus Antibody Concentrations (Pharmaceutical Product Development (PPD) ELISA) [ Time Frame: At 1 year post-vaccination ]
    Antibody concentrations are expressed as Geometric Mean Concentrations (GMC) in ELISA units per milliliter (EU/mL). The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-rubella virus antibody concentrations <5 EU/mL prior to vaccination.
38. Number of Subjects With Anti-mumps Virus Antibody Concentrations Above the Cut-off Value (PPD ELISA) [ Time Frame: At 1 year post-vaccination ]
    Anti-mumps virus antibody cut-off-value assessed was ≥ 10 ELISA units per milliliter (EU/mL)
39. Anti-mumps Virus Antibody Concentrations (PPD ELISA) [ Time Frame: At 2 years post-vaccination ]
    Antibody concentrations are expressed as Geometric Mean Concentrations (GMC) in ELISA units per milliliter (EU/mL). The analysis was performed on seronegative subjects. Seronegative subjects are subjects with anti-rubella virus antibody concentrations <5 EU/mL prior to vaccination.
40. Number of Subjects With Anti-mumps Virus Antibody Concentrations Above the Cut-off Value (PPD ELISA) [ Time Frame: At 2 years post-vaccination ]
    Anti-mumps virus antibody cut-off-value assessed was ≥ 10 ELISA units per milliliter (EU/mL)

Eligibility Criteria

• Ages Eligible for Study: 12 Months to 15 Months (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Subjects for whom the investigator believes their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study.
• Male or female between 12 and 15 months of age (e.g. from age 12 months until the day before age 16 months) at the time of vaccination.
• Written informed consent obtained from the parent/guardian of the subject.
• Healthy subjects as established by medical history and clinical examination before entering into the study.
• Have previously received three doses of 7-valent pneumococcal conjugate vaccine within the first year of life with the third dose administered at least 30 days prior to enrolment and vaccination with study vaccines.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
• Planned administration/ administration of a vaccine not foreseen by the study protocol from 30 days prior to vaccination until 42 days after vaccination, except for influenza vaccine and Hib vaccine.
• Previous vaccination against measles, mumps, rubella and/or varicella.
• Previous vaccination against hepatitis A or receipt of a fourth dose of pneumococcal conjugate vaccine.
• History of measles, mumps, rubella, varicella/zoster and hepatitis A diseases.
• Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the study.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required), including human immunodeficiency virus (HIV) infection.
• A family history of congenital or hereditary immunodeficiency.
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
• Hypersensitivity to latex
• Major congenital defects or serious chronic illness.
• History of any neurologic disorders or seizures, including febrile seizures.
• Acute disease at the time of enrolment.
• Administration of polyclonal immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period.

Contacts and Locations

Locations

United States, Alabama

GSK Investigational Site

Tuscaloosa, Alabama, United States, 35401

United States, Arkansas

GSK Investigational Site

Conway, Arkansas, United States, 72034

GSK Investigational Site

Jonesboro, Arkansas, United States, 72401

GSK Investigational Site

Little Rock, Arkansas, United States, 72205

United States, California

GSK Investigational Site

Anaheim, California, United States, 92804

GSK Investigational Site

Downey, California, United States, 90241

GSK Investigational Site

Fresno, California, United States, 93720

GSK Investigational Site

Huntington Beach, California, United States, 92647

GSK Investigational Site

Paramount, California, United States, 90723

GSK Investigational Site

Santa Ana, California, United States, 92701-4607

GSK Investigational Site

West Covina, California, United States, 91790

United States, Florida

GSK Investigational Site

Altamonte Springs, Florida, United States, 32701

United States, Georgia

GSK Investigational Site

Dalton, Georgia, United States, 30721

GSK Investigational Site

Marietta, Georgia, United States, 30062

United States, Idaho

GSK Investigational Site

Nampa, Idaho, United States, 83686

United States, Illinois

GSK Investigational Site

DeKalb, Illinois, United States, 60115

United States, Kansas

GSK Investigational Site

Arkansas City, Kansas, United States, 67005

United States, Kentucky

GSK Investigational Site

Bardstown, Kentucky, United States, 40004

United States, Louisiana

GSK Investigational Site

Bossier City, Louisiana, United States, 71111

GSK Investigational Site

Metairie, Louisiana, United States, 70006

United States, Maryland

GSK Investigational Site

Baltimore, Maryland, United States, 21021

United States, Massachusetts

GSK Investigational Site

Fall River, Massachusetts, United States, 02724

United States, Missouri

GSK Investigational Site

Kansas City, Missouri, United States, 64108

United States, Montana

GSK Investigational Site

Great Falls, Montana, United States, 59405

United States, Nevada

GSK Investigational Site

Henderson, Nevada, United States, 89015

United States, New York

GSK Investigational Site

Utica, New York, United States, 13502

United States, North Carolina

GSK Investigational Site

Cary, North Carolina, United States, 27518

GSK Investigational Site

Raleigh, North Carolina, United States, 27609

United States, Ohio

GSK Investigational Site

Cincinnati, Ohio, United States, 45245

GSK Investigational Site

Dayton, Ohio, United States, 45406

United States, Oklahoma

GSK Investigational Site

Tulsa, Oklahoma, United States, 74127

United States, Oregon

GSK Investigational Site

Gresham, Oregon, United States, 97030

United States, Pennsylvania

GSK Investigational Site

East Norriton, Pennsylvania, United States, 19401

GSK Investigational Site

Rydal, Pennsylvania, United States, 19046

United States, South Carolina

GSK Investigational Site

Charleston, South Carolina, United States, 29406

United States, Tennessee

GSK Investigational Site

Bristol, Tennessee, United States, 37620

GSK Investigational Site

Kingsport, Tennessee, United States, 37660

United States, Texas

GSK Investigational Site

Corpus Christi, Texas, United States, 78411

United States, Utah

GSK Investigational Site

Layton, Utah, United States, 84041

GSK Investigational Site

Provo, Utah, United States, 84604

GSK Investigational Site

Saint George, Utah, United States, 84790

GSK Investigational Site

Springville, Utah, United States, 84663

GSK Investigational Site

West Jordan, Utah, United States, 84088

United States, Virginia

GSK Investigational Site

Virginia Beach, Virginia, United States, 23454

United States, West Virginia

GSK Investigational Site

Huntington, West Virginia, United States, 25701

Puerto Rico

GSK Investigational Site

Bayamon, Puerto Rico, 00959

GSK Investigational Site

San Germán, Puerto Rico, 00683

GSK Investigational Site

San Juan, Puerto Rico, 00936-5067

Sponsors and Collaborators

GlaxoSmithKline

Investigators

• Study Director: GSK Clinical Trials; GlaxoSmithKline

More Information

Additional Information:

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research. 

Study Data/Documents: Clinical Study Report 

Identifier: 111870
For additional information about this study please refer to the GSK Clinical Study Register

Statistical Analysis Plan 

Identifier: 111870
For additional information about this study please refer to the GSK Clinical Study Register

Annotated Case Report Form 

Identifier: 111870
For additional information about this study please refer to the GSK Clinical Study Register

Individual Participant Data Set 

Identifier: 111870
For additional information about this study please refer to the GSK Clinical Study Register

Dataset Specification 

Identifier: 111870
For additional information about this study please refer to the GSK Clinical Study Register

Study Protocol 

Identifier: 111870
For additional information about this study please refer to the GSK Clinical Study Register

Informed Consent Form 

Identifier: 111870
For additional information about this study please refer to the GSK Clinical Study Register

Publications:

Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, Povey M, Da Costa C, Nicholson O, Innis BL. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months. J Pediatric Infect Dis Soc. 2015 Dec;4(4):339-48. doi: 10.1093/jpids/piu081. Epub 2014 Aug 7.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Berry AA, Abu-Elyazeed R, Diaz-Perez C, Mufson MA, Harrison CJ, Leonardi M, Twiggs JD, Peltier C, Grogg S, Carbayo A, Shapiro S, Povey M, Baccarini C, Innis BL, Henry O. Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin. Hum Vaccin Immunother. 2017 Jul 3;13(7):1516-1522. doi: 10.1080/21645515.2017.1309486. Epub 2017 May 8.

• Responsible Party: GlaxoSmithKline
• ClinicalTrials.gov Identifier: NCT00861744
• Other Study ID Numbers: 111870; 2011-005860-31 ( EudraCT Number )
• First Posted: March 13, 2009
• Results First Posted: November 4, 2011
• Last Update Posted: January 3, 2020
• Last Verified: December 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: IPD is available via the Clinical Study Data Request site (click on the link provided below)
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR)
• Time Frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
• Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
• URL: https://clinicalstudydatarequest.com/Posting.aspx?ID=3669

Keywords provided by GlaxoSmithKline:

Measles, Mumps, Rubella, Varicella Vaccine; Children; Immunogenicity; Safety; Humans; Combined Vaccine; Vaccines

Additional relevant MeSH terms:

Measles; Rubella; Mumps; Morbillivirus Infections; Paramyxoviridae Infections; Mononegavirales Infections; RNA Virus Infections; Virus Diseases; Infections; Rubivirus Infections; Togaviridae Infections; Rubulavirus Infections; Parotitis; Parotid Diseases; Salivary Gland Diseases; Mouth Diseases; Stomatognathic Diseases; Heptavalent Pneumococcal Conjugate Vaccine; Immunologic Factors; Physiological Effects of Drugs